In Use Case 1, the virtual twin modelling of the liver fibrosis progression is addressed with the objective of generating new mechanistic knowledge and  translating it into clinical interventions or prevention measures, which can slow down or prevent the liver fibrosis progression. The virtual twin permits to close the gap between data and mechanistic knowledge at cell and tissue level on one hand, and medical imaging and blood markers on the other hand. Despite a majority of MASLD patients never progress to advanced liver disease stages, they could die from cardiovascular diseases. Thus, the computer models to assist MASLD patient management need to contemplate cardiac complications, by implementing a multi-organ approach.